TEVA files Form 144 to sell 30,000 shares

TEVA PHARMACEUTICAL INDUSTRIES LIMITED filed a Form 144 notice for the proposed sale of 30,000 ordinary shares through Citigroup Global Markets Inc. with an indicated aggregate amount of $1,062,000.00 and listing on NYSE.

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LIMITED filed a Form 144 notice for the proposed sale of 30,000 ordinary shares through Citigroup Global Markets Inc. with an indicated aggregate amount of $1,062,000.00 and listing on NYSE.

The filing lists prior sales by Daniell Richard in early March 2026: 128,985 shares for $4,173,941.70 on 03/03/2026, 91,345 shares for $2,983,515.95 on 03/04/2026, and 17,295 shares for $547,704.98 on 03/05/2026. Shares outstanding are shown as 1,164,426,972 as of 05/05/2026.

Key Figures

Proposed sale: 30,000 shares Indicated aggregate amount: $1,062,000.00 Shares outstanding: 1,164,426,972 +3 more

6 metrics

Proposed sale 30,000 shares Form 144 securities to be sold

Indicated aggregate amount $1,062,000.00 Associated with the 30,000-share sale

Shares outstanding 1,164,426,972 as of 05/05/2026

Prior sale 1 128,985 shares sold 03/03/2026 for $4,173,941.70

Prior sale 2 91,345 shares sold 03/04/2026 for $2,983,515.95

Prior sale 3 17,295 shares sold 03/05/2026 for $547,704.98

Key Terms

Form 144, Ordinary Shares, Shares from rollover, Citigroup Global Markets Inc

4 terms

Form 144 regulatory

"filed a Form 144 notice for the proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Ordinary Shares financial

"ORDINARY SHARES | 03/03/2026 | SHARES FROM ROLLOVER"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Shares from rollover financial

"03/03/2026 | SHARES FROM ROLLOVER"

Citigroup Global Markets Inc other

"CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 filing report?

It reports a proposed sale of 30,000 ordinary shares through Citigroup Global Markets Inc. The filing shows an indicated aggregate amount of $1,062,000.00 and NYSE listing details.

Who is the selling party named in the Form 144 for TEVA?

The filing names Daniell Richard as the related person. The document shows prior March 2026 sales attributed to Daniell Richard in the included transactions list.

What recent sales by Daniell Richard are disclosed?

The filing lists three sales: 128,985 shares for $4,173,941.70 on 03/03/2026, 91,345 shares for $2,983,515.95 on 03/04/2026, and 17,295 shares for $547,704.98 on 03/05/2026.

Which broker is handling the proposed sale in the Form 144?

The proposed sale is listed with Citigroup Global Markets Inc. located at 390 Greenwich Street, New York, NY, as the broker handling the transaction.

How many TEVA shares are outstanding per the filing?

The filing shows 1,164,426,972 shares outstanding with an associated date of 05/05/2026 in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001726096
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Daniell Richard
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP EUROPEAN COMMERCIAL

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	30000	1062000.00	1164426972	05/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			30000	05/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniell Richard TEVA PHARMACUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	128985	4173941.70
Daniell Richard 124 DVORA HANEVI'A ST. 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/04/2026	91345	2983515.95
Daniell Richard TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/05/2026	17295	547704.98

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. 3D BASED ON INDICATIVE MARKET PRICE 35.40
Date of Notice	05/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)